Discussion: The combination of sEphB4-HSA and pembrolizumab has a favorable toxicity profile and favorable activity particularly among HPV-negative EphrinB2 positive patients with HNSCC. This evidence concerns the gene EFNB2 and head and neck squamous cell carcinoma.